.png){kind=icon}
.png){kind=icon}
Return
PROTAC delivery systems: Innovative approaches for cancer treatment
.png){kind=icon}
OA
AI
M
A
I
C
DOI：10.1016/j.biopha.2025.118892.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• PROTACs drive selective oncoprotein degradation for precision oncology. • Clinical translation of PROTACs faces challenges in bioavailability and toxicity. • Nanocarriers enhance PROTAC delivery, stability, and therapeutic index. • Polymeric and lipid-based nanoparticles of PROTACs show highest clinical translation potential. • NanoPROTACs pave the way for safer and more effective cancer therapies.
Keywords:
ADC
Antibody-drug conjugate
AR
Androgen receptor
BRo5
Beyond Lipinski’s “rule of five”
CIAP1
Cellular inhibitor of apoptosis protein
CRBN
Cereblon
DDS
Drug delivery systems
EPR
Enhanced permeability and retention
ER
Estrogen receptor
LBNP
Lipid-based nanoparticle
LBNPR
Lipid-based nanoPROTAC
MAb
Monoclonal antibody
MDM2
Murine double minute 2
P
Partition coefficient
POI
Protein of interest
PROTAC
PROTeolysis TArgeting Chimera
PPI
Protein-protein interaction
PSA
Prostate specific antigen
SMI
Small molecule inhibitor
TF
Transcription factor
TNBC
Triple negative breast cancer
UPS
Ubiquitin-Proteasome System
VHL
Von Hippel-Lindau
PROTAC
Protein degrader
Targeted therapy
Nanomedicine
Drug delivery
Cancer therapy
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
B
IF:
7.5
Papers:
1.6W
Citations:
8.2W
Organization
Cited Papers